Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the intracellular and extracellular concentrations of these various electrolytes and ions in Chronic Kidney Disease and Gitelman’sSyndrome and by addressing the underlying mitochondrial pathology and inflammation associated with Acute Kidney Disease.Unicycive Therapeutics was founded in 2016 and is headquartered in Los Altos, California.

Biotechnology

Health Care

Health Diagnostics

Unicycive Therapeutics

Shalabh Gupta, MD

Hannah Haddox

Teresa Miller

Satya Medicherla

Pramod Gupta

John Townsend

Guru Reddy

Doug Jermasek

Atul Khare, Ph.D., M.B.A.

The Leadership Team at Unicycive Therapeutics oversees the strategic direction, scientific innovation, corporate strategy, financial planning, and operational management to advance the development of therapies for kidney diseases. This team collectively ensures that the company remains at the forefront of medical research and development, while effectively navigating the complexities of the pharmaceutical industry to meet significant unmet medical needs.

Leadership Team

Scientific and Clinical Development

Leadership Team

About

Team members

Other teams at Unicycive Therapeutics

Scientific and Clinical Development